Alissa R Van Zutphen1, Martha M Werler, Marilyn M Browne, Paul A Romitti, Erin M Bell, Louise-Anne McNutt, Charlotte M Druschel, Allen A Mitchell. 1. Congenital Malformations Registry, New York State Department of Health, Albany, and the Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Rensselaer, New York; the Slone Epidemiology Center at Boston University, Boston, Massachusetts; and the Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa.
Abstract
OBJECTIVE: To investigate whether antihypertensive classes and specific medications in early pregnancy increase the risk of severe hypospadias and to assess prior associations detected for late-treated and untreated hypertension in the National Birth Defects Prevention Study. METHODS: Using telephone interviews from mothers of 2,131 children with severe hypospadias and 5,129 nonmalformed male control children for 1997-2009 births in a population-based case-control study, we estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) with multivariable logistic regression. We adjusted P values to account for multiple testing. RESULTS: Forty-eight (2.3%) case and 70 (1.4%) control mothers reported early pregnancy antihypertensive treatment, 45 (2.1%) case and 31 (0.6%) control mothers reported late treatment, and 315 (14.8%) case and 394 (7.7%) control mothers reported untreated hypertension. Selective β-blockers, centrally acting agents, renin-angiotensin system-acting agents, diuretics, and specific medications, methyldopa and atenolol, were not associated with hypospadias. Nonselective β-blockers (adjusted OR 3.22, 95% CI 1.47-7.05) were associated with hypospadias; however, P values adjusted for multiple testing were not statistically significant. We confirmed prior findings for associations between hypospadias and untreated hypertension (adjusted OR 2.09, 95% CI 1.76-2.48) and late initiation of treatment (adjusted OR 3.98, 95% CI 2.41-6.55). The increased risks would translate to severe hypospadias prevalences of 11.5, 17.7, and 21.9 per 10,000 births for women with untreated hypertension, nonselective β-blocker use, and late initiation of treatment, respectively. CONCLUSION: Our study suggests a relationship between hypospadias and the severity of hypertension. LEVEL OF EVIDENCE: II.
OBJECTIVE: To investigate whether antihypertensive classes and specific medications in early pregnancy increase the risk of severe hypospadias and to assess prior associations detected for late-treated and untreated hypertension in the National Birth Defects Prevention Study. METHODS: Using telephone interviews from mothers of 2,131 children with severe hypospadias and 5,129 nonmalformed male control children for 1997-2009 births in a population-based case-control study, we estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) with multivariable logistic regression. We adjusted P values to account for multiple testing. RESULTS: Forty-eight (2.3%) case and 70 (1.4%) control mothers reported early pregnancy antihypertensive treatment, 45 (2.1%) case and 31 (0.6%) control mothers reported late treatment, and 315 (14.8%) case and 394 (7.7%) control mothers reported untreated hypertension. Selective β-blockers, centrally acting agents, renin-angiotensin system-acting agents, diuretics, and specific medications, methyldopa and atenolol, were not associated with hypospadias. Nonselective β-blockers (adjusted OR 3.22, 95% CI 1.47-7.05) were associated with hypospadias; however, P values adjusted for multiple testing were not statistically significant. We confirmed prior findings for associations between hypospadias and untreated hypertension (adjusted OR 2.09, 95% CI 1.76-2.48) and late initiation of treatment (adjusted OR 3.98, 95% CI 2.41-6.55). The increased risks would translate to severe hypospadias prevalences of 11.5, 17.7, and 21.9 per 10,000 births for women with untreated hypertension, nonselective β-blocker use, and late initiation of treatment, respectively. CONCLUSION: Our study suggests a relationship between hypospadias and the severity of hypertension. LEVEL OF EVIDENCE: II.
Authors: P W Yoon; S A Rasmussen; M C Lynberg; C A Moore; M Anderka; S L Carmichael; P Costa; C Druschel; C A Hobbs; P A Romitti; P H Langlois; L D Edmonds Journal: Public Health Rep Date: 2001 Impact factor: 2.792
Authors: Robert L Davis; David Eastman; Heather McPhillips; Marsha A Raebel; Susan E Andrade; David Smith; Marianne Ulcickas Yood; Sascha Dublin; Richard Platt Journal: Pharmacoepidemiol Drug Saf Date: 2010-11-15 Impact factor: 2.890
Authors: Marijn M Brouwers; Loes F M van der Zanden; Robert P E de Gier; Evert J Barten; Gerhard A Zielhuis; Wouter F J Feitz; Nel Roeleveld Journal: BJU Int Date: 2009-09-14 Impact factor: 5.588
Authors: Jorieke E H Bergman; L Renée Lutke; Rijk O B Gans; Marie-Claude Addor; Ingeborg Barisic; Clara Cavero-Carbonell; Ester Garne; Miriam Gatt; Kari Klungsoyr; Nathalie Lelong; Catherine Lynch; Olatz Mokoroa; Vera Nelen; Amanda J Neville; Anna Pierini; Hanitra Randrianaivo; Anke Rissmann; David Tucker; Awi Wiesel; Helen Dolk; Maria Loane; Marian K Bakker Journal: Drug Saf Date: 2018-04 Impact factor: 5.606
Authors: Hussein Jamaladin; Iris A L M van Rooij; Loes F M van der Zanden; Marleen M H J van Gelder; Nel Roeleveld Journal: Paediatr Perinat Epidemiol Date: 2020-07-13 Impact factor: 3.980